Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:37:12.662Z.
Calculation as of: 2026-10-06T16:37:12.662Z.
Quote observation: 2026-10-06T16:35:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$70.30M
Price/FCF Ratio
N/A
TTM Avg
17.09
3Y Avg
24.44
5Y Avg
36.17
Market Cap
$69.48M
Price/FCF Ratio
3.55
TTM Avg
11.66
3Y Avg
7.20
5Y Avg
7.81
Market Cap
$69.31M
Price/FCF Ratio
N/A
TTM Avg
1291.26
3Y Avg
1291.26
5Y Avg
1291.26
Market Cap
$75.91M
Price/FCF Ratio
4.56
TTM Avg
5.17
3Y Avg
25.10
5Y Avg
25.10
Market Cap
$68.27M
Price/FCF Ratio
0.54
TTM Avg
0.74
3Y Avg
0.74
5Y Avg
0.74
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $72.51M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $70.30M | N/A | 17.09 | 24.44 | 36.17 |
| Hyperfine, Inc. (HYPR)vs › | $75.36M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.48M | 3.55 | 11.66 | 7.20 | 7.81 |
| MindWalk Holdings Corp. (HYFT)vs › | $69.31M | N/A | 1291.26 | 1291.26 | 1291.26 |
| SkinHealth Systems Inc. (SKIN)vs › | $75.91M | 4.56 | 5.17 | 25.10 | 25.10 |
| Outset Medical, Inc. (OM)vs › | $76.00M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $68.62M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.27M | 0.54 | 0.74 | 0.74 | 0.74 |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.05M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
